A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

Table 4 Predictors of mortality following ART initiation

Predictor at ART initiation	HR, 95% CI	P value	Model 1 adjusted HR, 95% CI	P value	Model 2 Adjusted HR, 95% CI	P value
Age (years)	1.04 (0.90 − 1.21)	0.57
BMI (kg/m²)	0.94 (0.78–1.14)	0.56
Karnofsky Performance Scale
Minor symptoms (90)	Reference
Moderate symptoms (80)	1.11 (0.11–10.63)	0.93
Unable to work (<80)	5.34 (0.55–51.38)	0.15
Current tuberculosis	3.01 (0.50–18.02)	0.23
WHO Stage
Stage I	Reference
Stage II	0.66 (0.04–10.49)	0.77
Stage III	0.85 (0.08–9.34)	0.89
Stage IV	1.80 (0.11–28.77)	0.68
CD4 Cell count (cells/μL)	0.99 (0.97–1.01)	0.22
Log₁₀ Plasma HIV-1 RNA (copies/mL)	3.00 (0.62–14.60)	0.17
Hemoglobin (g/dL)	0.59 (0.33–1.07)	0.08	0.51 (0.21–1.23)	0.13	0.41 (0.18–0.92)	0.03
Log₁₀ Angiopoietin-1 (ng/mL)	0.25 (0.005–13.63)	0.50
Log₁₀ Angiopoietin-2 (ng/mL)	18.85 (1.52–233.7)	0.02	41.31 (0.82–2,086)	0.06	75.06 (1.98–2,846)	0.02
Log₁₀ ANG-2/ANG-1 ratio	19.99 (1.66–240.5)	0.02
Log₁₀ s-ICAM (ng/mL)	10,062 (18.29–5,536,091)	0.004	355.8 (0.22–581,538)	0.12
Log₁₀ E-selectin (ng/mL)	11.17 (0.18–696.4)	0.25
Log₁₀ VCAM (ng/mL)	9.33 (0.14–644.0)	0.30